Bio‑Rad Lowers 2026 Revenue Outlook, Expands Margin Target After Q1 Loss

Bio‑Rad’s Q1 2026 results underscore a stark contrast between GAAP and non‑GAAP performance. Net sales held steady at $592.1 million, a modest 1.1% year‑over‑year increase, while GAAP gross margin remained flat at 52.3%. Operating income rose to $34.1 million, but a $527.1 million GAAP loss—driven largely by a fair‑value write‑down on its investment in Sartorius AG—dragged diluted EPS to –$19.55.

On a non‑GAAP basis, the company posted a $50.9 million profit, translating to $1.89 earnings per share, and a slightly lower gross margin of 53.1% (down from 53.8%). Operating cash flow of $108.1 million and free cash flow of $78.1 million demonstrate that the business continues to generate liquidity despite the accounting loss.

Guidance shift. Management now expects 2026 non‑GAAP, currency‑neutral revenue to decline up to 3% or grow as little as 0.5%, a downgrade from the prior +0.5%‑+1.5% outlook. Conversely, the operating‑margin range has been broadened to 10.0%‑12.0% from 12.0%‑12.5%, reflecting confidence that cost‑control initiatives and product‑mix improvements can offset softer top‑line growth.

CEO Norman Schwartz highlighted resilience in “challenging academic markets and the ongoing Middle‑East conflict,” noting that the company’s cash position—$507.2 million in cash and $1.06 billion in short‑term investments—provides flexibility for continued share repurchases (176 k shares this quarter) and strategic investments.

Balance‑sheet health. Total assets stand at $9.79 billion against $2.94 billion in liabilities, leaving stockholders’ equity at $6.85 billion. Long‑term debt net is $802.9 million, with $400.5 million maturing within the year, a manageable profile given the strong operating cash flow.

The market gave the news a muted reaction; Bio‑Rad shares traded around $280.10, up 1.8% on the day, but the broader S&P 500 posted a similar gain, suggesting investors are weighing the guidance downgrade against the solid cash generation. The company will discuss the results on a conference call at 2:00 PM PT on April 30.

Forward‑looking statements in the filing caution that outcomes depend on geopolitical stability, macro‑economic conditions, supply‑chain continuity, regulatory approvals, and the successful integration of recent acquisitions.

Analysts note that the revised margin target could be a catalyst for upside if Bio‑Rad can sustain operating efficiencies while navigating a sluggish academic spend environment.